Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
17 août 2023 07h30 HE
|
Excision BioTherapeutics
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primatesData are a key component of scientific rationale supporting the ongoing...
Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
20 juil. 2023 07h00 HE
|
Excision BioTherapeutics
EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and...
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
01 juin 2023 09h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases,...
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
20 oct. 2022 08h00 HE
|
Excision BioTherapeutics
Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the...
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
29 sept. 2022 07h30 HE
|
Excision BioTherapeutics
CIRM Grant of $6.85 million supports the first-in-human clinical study evaluating the safety and efficacy of EBT-101 in participants people living with HIVEBT-101 is an in vivo CRISPR-based...
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
15 sept. 2022 07h00 HE
|
Excision BioTherapeutics
EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will evaluate the safety and efficacy of EBT-101 in participants...
Excision BioTherapeutics to Present at Upcoming Conferences
09 sept. 2022 07h30 HE
|
Excision BioTherapeutics
SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases,...
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET
07 juin 2022 16h05 HE
|
Excision BioTherapeutics
SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced...
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
17 mai 2022 08h00 HE
|
Excision BioTherapeutics
EBT-101 achieves HIV excision without detectable off-target effectsPoster presentation to take place today from 5:30 – 6:30 PM ET SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Excision...
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
27 janv. 2022 07h30 HE
|
Excision BioTherapeutics
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE...